Osteoblastoma of the mandible: A rare locally aggressive benign tumour
Dear Editor, (Source: Oral Oncology)
Source: Oral Oncology - May 17, 2018 Category: Cancer & Oncology Authors: Saad Khokhar, Shadaab Mumtaz, Steven Liggins Tags: Letter to the editor Source Type: research
Plasmacytoma
Dear Editor, (Source: Oral Oncology)
Source: Oral Oncology - May 17, 2018 Category: Cancer & Oncology Authors: Shadaab Mumtaz Tags: Letter to the editor Source Type: research
Outcomes and prognostic factors for parotid acinic cell Carcinoma: A National Cancer Database study of 2362 cases
Salivary gland carcinomas represent 1 –3% of all head and neck malignancies. According to various population-based studies, acinic cell carcinoma (ACC) is often described as one of the top four most common parotid malignancies, trailing mucoepidermoid carcinoma, adenocarcinoma and occasionally adenoid cystic carcinoma in incidence and accounting for approximately 10–12% of all salivary carcinomas [1–6]. In addition, there are wide ranges of variability in studies describing the risk of nodal disease, treatment recommendations and prognosis of this cancer particularly when consideration is given to “high grade” ve...
Source: Oral Oncology - May 14, 2018 Category: Cancer & Oncology Authors: Claudia Scherl, Masanari G. Kato, Evren Erkul, Evan M. Graboyes, Shaun A. Nguyen, Angela C. Chi, Patrick F. Morgan, Terry A. Day Source Type: research
Primary thyroid angiosarcoma: A systematic review
Thyroid angiosarcoma (TAS) represents a rare malignancy and constitutes less than 1% of all sarcomas [1]. TAS is an aggressive disease, characterized by severe local course and rapid metastatic dissemination, leading to a poor prognosis. It arises from endothelial cells. In the past years, the real existence of TAS as primary tumor in the thyroid gland has been debated due to its unusual pathological finding [2]. The distribution is predominant in female and primarily affects elderly patients with a history of goiter and rapidly enlarging neck masses [1]. (Source: Oral Oncology)
Source: Oral Oncology - May 12, 2018 Category: Cancer & Oncology Authors: F. De Felice, E. Moscatelli, S. Orelli, N. Bulzonetti, D. Musio, V. Tombolini Tags: Review Source Type: research
Clinicopathological characteristics and outcome of 31 patients with ETV6-NTRK3 fusion gene confirmed (mammary analogue) secretory carcinoma of salivary glands
Salivary gland cancers comprise a wide histological spectrum with more than twenty different subtypes [1]. In 2010, a new entity of salivary gland cancer was described by Sk álová et al., characterized by the presence of the ETV6-NTRK3 fusion gene [2]. The histopathological appearance resembles secretory carcinoma of the breast, and both tumors share the ETV6-NTRK3 fusion gene, hence the proposed name was mammary analogue secretory carcinoma (MASC). In the updated 201 7 WHO classification, MASC is acknowledged and referred to as ‘secretory carcinoma’, to standardize nomenclature amongst different organ sites [1]. (Source: Oral Oncology)
Source: Oral Oncology - May 11, 2018 Category: Cancer & Oncology Authors: E. Boon, M.H. Valstar, W.T.A. van der Graaf, E. Bloemena, S.M. Willems, C.A. Meeuwis, P.J. Slootweg, L.A. Smit, M.A.W. Merkx, R.P. Takes, J.H.A.M. Kaanders, P.J.T.A. Groenen, U.E. Flucke, C.M.L. van Herpen Source Type: research
Mat é consumption association with upper aerodigestive tract cancers: A systematic review and meta-analysis
Malignancies of the upper aerodigestive tract (UADT) are one of the most common worldwide [1,2]. UADT malignancies include oral, pharyngeal, laryngeal, and esophageal cancers. Together, UADT account for more than one million new cases of cancer and more than eight hundred thousand deaths globally every year [3]. These malignancies are multifactorial diseases and several factors are associated with their development, such as excess of alcohol consumption and tobacco use, viral infections, and some occupational exposures [4 –8]. (Source: Oral Oncology)
Source: Oral Oncology - May 11, 2018 Category: Cancer & Oncology Authors: Fernanda Weber Mello, Fernanda Marcello Scotti, Gilberto Melo, Saman Warnakulasuriya, Eliete Neves Silva Guerra, Elena Riet Correa Rivero Tags: Review Source Type: research
Human papillomavirus detection in gargles, tonsil brushings, and frozen tissues in cancer-free patients
Despite strong evidence of the implication of human papillomavirus (HPV) infection in the aetiology of oropharyngeal cancer, the detection of infection and its earliest sequelae lesions in the tonsil remains elusive. In our study of the natural history of HPV infection and precancerous lesions in the tonsils (SPLIT), we evaluated tonsil brushings of 692 French patients (median age 26, interquartile range 19 –35 years) and rinses/gargles (hereinafter referred to as “gargles”) from a subset of 268 adults who had all undergone tonsillectomy for non-cancerous reasons [1]. (Source: Oral Oncology)
Source: Oral Oncology - May 11, 2018 Category: Cancer & Oncology Authors: J.D. Combes, C. Clavel, V. Dalstein, T. Gheit, G.M. Clifford, M. Tommasino, S. Franceschi, J. Lacau St Guily, for the SPLIT study group Tags: Commentary Source Type: research
AJCC 8th Edition oral cavity squamous cell carcinoma staging – Is it an improvement on the AJCC 7th Edition?
The 8th Edition of the American Joint Committee on Cancer (AJCC) Staging Manual, Head and Neck Section has recently been released and will have been introduced into clinical practice at the commencement of 2018 [1]. The 8th Edition represents the most significant changes to Oral Cavity cancer staging since the first edition of the American Joint Committee on Cancer Staging Manual was published in 1977 [2]. (Source: Oral Oncology)
Source: Oral Oncology - May 10, 2018 Category: Cancer & Oncology Authors: Katherine Pollaers, Anton Hinton-Bayre, Peter L. Friedland, Camile S. Farah Source Type: research
Bisphosphonate-related osteonecrosis of the human jaw: A combined 3D assessment of bone descriptors by histology and synchrotron radiation-based microtomography
Bisphosphonate-related osteonecrosis of the jaw (BRONJ), as other bone diseases, is supposed to be associated with an unbalanced bone remodeling process: thus, the full comprehension of the pathophysiology is fundamental to advance its treatment. (Source: Oral Oncology)
Source: Oral Oncology - May 8, 2018 Category: Cancer & Oncology Authors: Alessandra Giuliani, Giovanna Iezzi, Marco Mozzati, Giorgia Gallesio, Serena Mazzoni, Giuliana Tromba, Franco Zanini, Adriano Piattelli, Carmen Mortellaro Tags: Letter to the editor Source Type: research
Impact of radical treatments on survival in locally advanced T4a and T4b buccal mucosa cancers: Selected surgically treated T4b cancers have similar control rates as T4a
The American Joint Committee on Cancer (AJCC) staging system classifies locally advanced squamous cell carcinoma of the buccal mucosa as T4a (moderately advanced local disease) when it invades the bone, skin or extrinsic muscles of the tongue and T4b (very advanced local disease) when it invades masticator space (MS), pterygoid plates (PP), skull base, and/or encases the internal carotid artery [1]. The purpose of this separation into T4a and T4b was to emphasize the high rate of unresectability, local recurrence [2,3] and poor prognosis in T4b tumors [4]. (Source: Oral Oncology)
Source: Oral Oncology - May 6, 2018 Category: Cancer & Oncology Authors: Manish D. Mair, Noopur Sawarkar, Santosh Nikam, Rajiv Sarin, Deepa Nair, Tejpal Gupta, Pankaj Chaturvedi, Anil D'cruz, Sudhir Nair Source Type: research
MicroRNA-155, -185 and -193b as biomarkers in human papillomavirus positive and negative tonsillar and base of tongue squamous cell carcinoma
Human papillomavirus (HPV) is now acknowledged as a risk factor for oropharyngeal squamous cell carcinoma (OPSCC), where tonsillar and base of tongue cancer (TSCC/BOTSCC) make up most HPV-positive (HPV+) cases, and as causative for the recent increase in the incidence of OPSCC [1 –8]. Of note, HPV+ TSCC/BOTSCC patients treated with radiotherapy alone have better disease-specific-survival (DSS) than those with corresponding HPV-negative (HPV−) cancer, with 80% vs. 40% 3-year DSS [9–14]. Due to poor prognosis in the HPV− group predominantly, head-neck cancer treatment has been intensified in the past years, with acce...
Source: Oral Oncology - May 4, 2018 Category: Cancer & Oncology Authors: Cinzia Bersani, Michael Mints, Nikolaos Tertipis, Linnea Haeggblom, Anders N äsman, Mircea Romanitan, Tina Dalianis, Torbjörn Ramqvist Source Type: research
The role of protein methyltransferases as potential novel therapeutic targets in squamous cell carcinoma of the head and neck
Over the past decade, multiple studies have uncovered the significance of protein methylation in cancer development and progression. Protein lysine (PKMTs) and arginine (PRMTs) methyltransferases comprise a group of 62 enzymes that mediate the reversible deposition of methyl groups on lysine and arginine residues, respectively, on either histone or non-histone substrates. Protein demethylases (PDMTs) comprise approximately 30 enzymes and they erase these marks. Studies conducted by the Cancer Genome Atlas (TCGA) consortium have revealed multiple genetic and expression level alterations in these enzymes in multiple cancer t...
Source: Oral Oncology - May 3, 2018 Category: Cancer & Oncology Authors: Vassiliki Saloura, Theodore Vougiouklakis, Cem Sievers, Kyunghee Burkitt, Yusuke Nakamura, Gordon Hager, Carter van Waes Tags: Review Source Type: research
Interobserver variations in the delineation of target volumes and organs at risk and their impact on dose distribution in intensity-modulated radiation therapy for nasopharyngeal carcinoma
Intensity-modulated radiotherapy (IMRT) has better clinic outcomes in the treatment of head and neck cancer, achieving more accurate target dose distribution and better protection of normal tissues [1 –3]. However, the premise is that the planning target volumes (PTVs) and organs at risk (OARs) must be accurately delineated. The treatment plan should be designed so that the prescribed dose can accurately cover the tumor target site, whereas the dose to the OARs does not exceed the established l imit. (Source: Oral Oncology)
Source: Oral Oncology - May 2, 2018 Category: Cancer & Oncology Authors: Ying-lin Peng, Li Chen, Guan-zhu Shen, Ya-ning Li, Ji-jin Yao, Wei-wei Xiao, Lin Yang, Shu Zhou, Jia-xin Li, Wan-qin Cheng, Ying Guan, Hai-qun Xia, Shuai Liu, Chong Zhao, Xiao-wu Deng Source Type: research
Depth of invasion, size and number of metastatic nodes predicts extracapsular spread in early oral cancers with occult metastases
Oral cancer is a major health problem worldwide with 300,373 new cases detected in the year 2012 [1]. It is the most common cancer in Indian men and fifth most common cancer amongst females [2]. The presence of nodal metastasis in oral cancers is one of the most important prognostic factors that may decrease survival by 50% [3]. It is important to note that clinically node negative (c N0) oral cancer patients harbor occult nodal metastasis to the range of 13 –53% [4]. This occult nodal metastasis may also have Extracapsular spread (ECS) that adversely affects survival [5]. (Source: Oral Oncology)
Source: Oral Oncology - May 2, 2018 Category: Cancer & Oncology Authors: Manish D. Mair, Rathan Shetty, Deepa Nair, Yash Mathur, Sudhir Nair, Anuja Deshmukh, Shiva Thiagarajan, Gouri Pantvaidya, Sarbani Lashkar, Kumar Prabhash, Devendra Chaukar, Prathmesh Pai, Anil D. Cruz, Pankaj Chaturvedi Source Type: research
Predictors of oropharyngeal cancer survival in Europe
Cancers arising in the oral cavity and pharynx have an estimated global burden of 442,760 incident cases and 241,458 deaths each year [1]. Tobacco smoking and alcohol consumption explain nearly 70% of these cancers [2,3]. Infection by Human PapillomaVirus (HPV), specifically type 16 (HPV16) causes a subset of cancers, particularly those arising at the tonsil, oropharynx, soft palate and base of the tongue (collectively referred to as oropharyngeal cancers-OPC) [4]. Further, HPV16-positive (HPV16+) OPC is described to be epidemiologically, molecularly and clinically distinct from HPV16-negative (HPV16-) OPC [5]. (Source: Oral Oncology)
Source: Oral Oncology - May 2, 2018 Category: Cancer & Oncology Authors: D. Anantharaman, A. Billot, T. Waterboer, T. Gheit, B. Abedi-Ardekani, P. Lagiou, A. Lagiou, W. Ahrens, I. Holc átová, F. Merletti, K. Kjaerheim, J. Polesel, L. Simonato, L. Alemany, M. Mena Cervigon, T.V. Macfarlane, A. Znaor, P.J. Thomson, M. Robinson Source Type: research
